125 related articles for article (PubMed ID: 38687941)
1. Tumor-targeted gypenoside nanodrug delivery system with double protective layers.
Lai Z; Bai F; Pu T; Li J; Wu L; Zhou Z; Yang N
J Cancer Res Ther; 2024 Apr; 20(2):684-694. PubMed ID: 38687941
[TBL] [Abstract][Full Text] [Related]
2. In vivo Targeting of Liver Cancer with Tissue- and Nuclei-Specific Mesoporous Silica Nanoparticle-Based Nanocarriers in mice.
Ding Z; Wang D; Shi W; Yang X; Duan S; Mo F; Hou X; Liu A; Lu X
Int J Nanomedicine; 2020; 15():8383-8400. PubMed ID: 33149582
[TBL] [Abstract][Full Text] [Related]
3. Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier.
Lv Y; Li J; Chen H; Bai Y; Zhang L
Int J Nanomedicine; 2017; 12():4361-4370. PubMed ID: 28652738
[TBL] [Abstract][Full Text] [Related]
4. RGD conjugated liposome-hollow silica hybrid nanovehicles for targeted and controlled delivery of arsenic trioxide against hepatic carcinoma.
Fei W; Zhang Y; Han S; Tao J; Zheng H; Wei Y; Zhu J; Li F; Wang X
Int J Pharm; 2017 Mar; 519(1-2):250-262. PubMed ID: 28109899
[TBL] [Abstract][Full Text] [Related]
5. A dual-functional HER2 aptamer-conjugated, pH-activated mesoporous silica nanocarrier-based drug delivery system provides in vitro synergistic cytotoxicity in HER2-positive breast cancer cells.
Shen Y; Li M; Liu T; Liu J; Xie Y; Zhang J; Xu S; Liu H
Int J Nanomedicine; 2019; 14():4029-4044. PubMed ID: 31213813
[No Abstract] [Full Text] [Related]
6. Co-delivery of sorafenib and siVEGF based on mesoporous silica nanoparticles for ASGPR mediated targeted HCC therapy.
Zheng G; Zhao R; Xu A; Shen Z; Chen X; Shao J
Eur J Pharm Sci; 2018 Jan; 111():492-502. PubMed ID: 29107835
[TBL] [Abstract][Full Text] [Related]
7. Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence.
Zhang F; Jia Y; Zheng X; Shao D; Zhao Y; Wang Z; Dawulieti J; Liu W; Sun M; Sun W; Pan Y; Cui L; Wang Y; He K; Zhang M; Li J; Dong WF; Chen L
Acta Biomater; 2019 Dec; 100():352-364. PubMed ID: 31563690
[TBL] [Abstract][Full Text] [Related]
8. pH-Sensitive mesoporous silica nanoparticles anticancer prodrugs for sustained release of ursolic acid and the enhanced anti-cancer efficacy for hepatocellular carcinoma cancer.
Li T; Chen X; Liu Y; Fan L; Lin L; Xu Y; Chen S; Shao J
Eur J Pharm Sci; 2017 Jan; 96():456-463. PubMed ID: 27771513
[TBL] [Abstract][Full Text] [Related]
9. Ultrasound-Triggered Destruction of Folate-Functionalized Mesoporous Silica Nanoparticle-Loaded Microbubble for Targeted Tumor Therapy.
Lv Y; Cao Y; Li P; Liu J; Chen H; Hu W; Zhang L
Adv Healthc Mater; 2017 Sep; 6(18):. PubMed ID: 28671341
[TBL] [Abstract][Full Text] [Related]
10. EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery.
Xie X; Li F; Zhang H; Lu Y; Lian S; Lin H; Gao Y; Jia L
Eur J Pharm Sci; 2016 Feb; 83():28-35. PubMed ID: 26690044
[TBL] [Abstract][Full Text] [Related]
11. Natural gelatin capped mesoporous silica nanoparticles for intracellular acid-triggered drug delivery.
Zou Z; He D; He X; Wang K; Yang X; Qing Z; Zhou Q
Langmuir; 2013 Oct; 29(41):12804-10. PubMed ID: 24073830
[TBL] [Abstract][Full Text] [Related]
12. A dual-sensitive mesoporous silica nanoparticle based drug carrier for cancer synergetic therapy.
Zhang J; Shen B; Chen L; Chen L; Meng Y; Feng J
Colloids Surf B Biointerfaces; 2019 Mar; 175():65-72. PubMed ID: 30522009
[TBL] [Abstract][Full Text] [Related]
13. Smart MSN-Drug-Delivery System for Tumor Cell Targeting and Tumor Microenvironment Release.
Dong JH; Ma Y; Li R; Zhang WT; Zhang MQ; Meng FN; Ding K; Jiang HT; Gong YK
ACS Appl Mater Interfaces; 2021 Sep; 13(36):42522-42532. PubMed ID: 34463488
[TBL] [Abstract][Full Text] [Related]
14. Mesoporous Silicon Nanoparticles with Liver-Targeting and pH-Response-Release Function Are Used for Targeted Drug Delivery in Liver Cancer Treatment.
Wei J; Tan Y; Bai Y; He J; Cao H; Guo J; Su Z
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473773
[TBL] [Abstract][Full Text] [Related]
15. Gypenoside XLIX loaded nanoparticles targeting therapy for renal fibrosis and its mechanism.
Liu Q; Chen X; Kan M; Yang J; Gong Q; Jin R; Dai Y; Jin J; Zang H
Eur J Pharmacol; 2021 Nov; 910():174501. PubMed ID: 34529980
[TBL] [Abstract][Full Text] [Related]
16. Negative-charge-functionalized mesoporous silica nanoparticles as drug vehicles targeting hepatocellular carcinoma.
Xie M; Xu Y; Shen H; Shen S; Ge Y; Xie J
Int J Pharm; 2014 Oct; 474(1-2):223-31. PubMed ID: 25149125
[TBL] [Abstract][Full Text] [Related]
17. Facile Synthesis of Three Types of Mesoporous Silica Microspheres as Drug Delivery Carriers and their Sustained-Release Properties.
Zhu Y; Wang B; Chen J; He J; Qiu X
Curr Drug Deliv; 2023; 20(9):1337-1350. PubMed ID: 35713141
[TBL] [Abstract][Full Text] [Related]
18. Gypenoside L, Isolated from Gynostemma pentaphyllum, Induces Cytoplasmic Vacuolation Death in Hepatocellular Carcinoma Cells through Reactive-Oxygen-Species-Mediated Unfolded Protein Response.
Zheng K; Liao C; Li Y; Fan X; Fan L; Xu H; Kang Q; Zeng Y; Wu X; Wu H; Liu L; Xiao X; Zhang J; Wang Y; He Z
J Agric Food Chem; 2016 Mar; 64(8):1702-11. PubMed ID: 26870999
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome c end-capped mesoporous silica nanoparticles as redox-responsive drug delivery vehicles for liver tumor-targeted triplex therapy in vitro and in vivo.
Zhang B; Luo Z; Liu J; Ding X; Li J; Cai K
J Control Release; 2014 Oct; 192():192-201. PubMed ID: 25034575
[TBL] [Abstract][Full Text] [Related]
20. Temperature-sensitive copolymer-coated fluorescent mesoporous silica nanoparticles as a reactive oxygen species activated drug delivery system.
Yu F; Wu H; Tang Y; Xu Y; Qian X; Zhu W
Int J Pharm; 2018 Jan; 536(1):11-20. PubMed ID: 29146540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
